Eliminating solid tumors with AI-driven, multiplex gene-edited CAR-T cells

Advancing cell therapies that break through immunosuppressive tumor barriers, enabling effective and durable cancer control

About

Science

Our Science

Redefining CAR-T with a next-generation approach:

AI-powered multiplex gene editing to overcome the immunosuppressive tumor microenvironment (TME) and drive superior efficacy in solid tumors.

AI-Driven Design

Harnessing advanced machine learning to identify and optimize multiplex gene-editing combinations, enabling CAR-T cells to resist TME suppression and enhance durability in solid tumors.

Multiplex Gene Editing

Utilizing cutting-edge gene editing to simultaneously engineer multiple suppressive pathway knockouts, enhancing CAR-T function and persistence in highly immunosuppressive environments.

Allogeneic CAR-T

Our healthy donor-derived CAR-T cells are designed for off-the-shelf accessibility and optimized to withstand the harsh conditions of the solid tumor microenvironment, ensuring sustained potency and therapeutic impact.

Meet the Team

Co-Founder, CEO

Aaron Edwards, MSc2, MBA

With a decade in cellular immunotherapy, Aaron has driven advancements in CAR-T and TCR-T therapies at bluebird bio, Beam Therapeutics (BEAM-201), Eli Lilly, and more. With a Harvard MS/MBA blending science and business, he leads KiraGen Bio’s mission to develop next-generation multiplex-edited cell therapies, overseeing strategy, fundraising, and partnerships.

Co-Founder, CSO

Ryan Murray, PhD

Ryan drives KiraGen Bio’s research strategy, pioneering next-generation CAR-T therapies for solid tumors. With a decade in cellular engineering at bluebird bio and Beam Therapeutics (BEAM-201), his expertise spans synthetic biology, tumor immunosuppression, and AI-driven gene editing. His PhD from Northeastern focused on overcoming TME-mediated resistance in NSCLC, shaping KiraGen’s approach to tackling solid tumors.

AI Scientist, Head of Immunoinformatics

Tessa Green, PhD

A biophysicist and data scientist specializing in single-cell transcriptomics and machine learning, Tessa developed scPerturb, a statistical tool for perturbation analysis published in Nature Methods. At Harvard Medical School, she built computational tools for single-cell analysis, generative models, and immunology research. At KiraGen Bio, she leads AI-driven approaches for optimizing gene edits and enhancing CAR-T therapies.

Associate Director of Platform Development

MarkVic Naniong

MarkVic Naniong brings a decade of biotech experience in CMC development for gene editors, allo CAR-T, and iPSC-derived therapies. At Tome Biosciences, he led iPSC process development, and at Beam Therapeutics, he contributed to BEAM-201’s clinical advancement. Now at KiraGen, he applies his expertise in CMC and platform development to drive R&D and clinical programs.

Scientist

Gabriella Lime, MS

With an MS in Molecular and Cell Biology from Brandeis, Gabriella specializes in gene editing. She has advanced RNA, DNA, and base editing at Beam, Aera, Prime Medicine, and Mammoth Biosciences, optimizing CRISPR and CAR-T systems for ocular, immunology, and oncology applications. At KiraGen Bio, she continues her work in therapeutic gene editing, advancing CAR-T for solid tumors.

Associate Scientist

Avery Houston, BS

A biotechnology researcher specializing in T-cell engineering and multiplexed gene editing, Avery has contributed to CAR-T optimization at Chroma Medicine, immune modulation at Dragonfly Therapeutics, and process development at RegenX and Homology Medicines. At KiraGen Bio, he advances CAR-T engineering, target screening, and functional assay development.